Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes.
about
rDNA insulin glargine U300 - a critical appraisalSafety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysisPharmacodynamic and pharmacokinetic evaluation of insulin glargine U300 for the treatment of type 1 diabetes.Pharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL in the treatment of diabetes and their clinical relevance.A review of the safety and efficacy data for insulin glargine 300 units/ml, a new formulation of insulin glargine.Efficacy and Safety of Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in High-Risk and Low-Risk Patients with Type 2 Diabetes Stratified Using Common Clinical Performance MeasuresInsulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus.Continuous Glucose Monitoring During Basal-Bolus Therapy Using Insulin Glargine 300 U mL(-1) and Glargine 100 U mL (-1) in Japanese People with Type 1 Diabetes Mellitus: A Crossover Pilot Study.New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1).New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2).Achieve control: a pragmatic clinical trial of insulin glargine 300 U/mL versus other basal insulins in insulin-naïve patients with type 2 diabetes.New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus.The past, present, and future of basal insulins.Controlled release of biologics for the treatment of type 2 diabetes.Insulin Glargine 300 U/mL: A Review in Diabetes Mellitus.Advances in Insulin Therapy: A Review of New Insulin Glargine 300 Units/mL in the Management of DiabetesEuglycaemic glucose clamp: what it can and cannot do, and how to do it.Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glargine 300 U/mL.Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice.Treatment Dosing Patterns and Clinical Outcomes for Patients with Type 2 Diabetes Starting or Switching to Treatment with Insulin Glargine (300 Units per Milliliter) in a Real-World Setting: A Retrospective Observational Study.Understanding concentrated insulins: a systematic review of randomized controlled trials.Switching basal insulins in type 2 diabetes: practical recommendations for health care providers.Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4).Clinical Challenges With Concentrated Insulins: Setting the Record Straight.LY2963016 Insulin Glargine and Insulin Glargine (Lantus) Produce Comparable Pharmacokinetics and Pharmacodynamics at Two Dose Levels.The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes.High Concentration Insulin.Basal-Bolus Insulin Therapy with Gla-300 During Hospitalization Reduces Nocturnal Hypoglycemia in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Study.Advances in Basal Insulin Therapy.U300 Insulin Glargine: A Novel Basal Insulin for Type 1 and Type 2 Diabetes.
P2860
Q28077366-24CA0D55-EC09-4BAF-A3EB-105C60488919Q28078467-FBA9491A-1E76-4E1F-966C-EE75D714246BQ30244827-1503F5CA-C691-466F-BB1F-E25695C8A5B8Q30248803-3F788D29-219F-4442-84ED-FAF76DC93143Q30978373-CFFA7175-C3E5-4EFA-AB88-B4237AEB49C7Q33727441-E81CA9CF-C279-4AA2-AAC4-BC4A82750C76Q33884391-A02D310C-D8BB-4B47-964A-4665C36FD568Q35772552-EB3529C0-903C-4990-AA16-89797743D274Q37343841-54EB1FA4-A021-4CEA-B33E-C4A1E2AB74BBQ37343847-CD0C7371-8926-4076-B3D2-9616BD9F921AQ38386958-81B439CF-8EF9-41E6-AD7D-71FB1C8CB8E6Q38559945-599D85BE-1375-4C94-9FF4-741F79EBC4E7Q38618376-DC779E64-0A24-4E81-98BB-9621F93483CDQ38665753-41D66456-CE0D-464B-A22F-C0464D2CFBA5Q38715053-FCC197BD-FB6A-44BD-90A5-8AFF1C98C666Q38811608-48C514F1-73FB-4C59-92E1-49A198061656Q38871135-06226087-E3F9-445F-9E93-7A9625EC5335Q38971612-84F4AD60-93E8-45B1-A23E-861E959A623CQ46199321-B7098DAF-6058-4F63-94DC-1253D5E287A2Q47192711-5217CBC3-9FA4-4F57-AA94-216BED4D1193Q47322851-6DBC5E8E-0E15-4508-933F-8BED77178035Q48088343-2D620F00-F255-406F-AF0B-C9B4ED68C52CQ48201978-07E93107-6AB4-4545-83FC-AAC55B35D4D9Q49899781-F751B807-CFCF-405F-B0D9-1948D7182AB2Q49899858-585F07AD-1CEA-4512-A75C-F89A908EAC74Q53449720-3EA661F4-EB29-407A-9957-59AD29F24356Q55007996-0E10729D-88F0-4EF1-BB4A-7E20ED96A31DQ55078513-20E015B2-6699-4DF7-AE18-9AF963B4BD91Q55309585-609917CE-5E22-41B5-819A-50390240FB93Q55402139-7C4D0517-ADB1-4E4A-9AF6-4C3B4A1D9C03
P2860
Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Single-dose new insulin glargi ...... n people with type 1 diabetes.
@ast
Single-dose new insulin glargi ...... n people with type 1 diabetes.
@en
type
label
Single-dose new insulin glargi ...... n people with type 1 diabetes.
@ast
Single-dose new insulin glargi ...... n people with type 1 diabetes.
@en
prefLabel
Single-dose new insulin glargi ...... n people with type 1 diabetes.
@ast
Single-dose new insulin glargi ...... n people with type 1 diabetes.
@en
P2093
P2860
P356
P1476
Single-dose new insulin glargi ...... n people with type 1 diabetes.
@en
P2093
A Fukuzaki
L Teichert
M Shiramoto
R H A Becker
P2860
P304
P356
10.1111/DOM.12415
P577
2014-12-22T00:00:00Z